The establishment of kidney cancer organoid line in drug testing
Cancer Medicine · 2024-06 · 13 (12)
DOI: 10.1002/cam4.7432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 26.06.2024. Verfasst von Ryan Tsz-Hei Tse und 12 weiteren Autor:innen. Beteiligte Einrichtung: S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Organoids, Kidney Neoplasms, Carcinoma, Renal Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese University of Hong Kong.
Abstract (Originalsprache)
Introduction
Kidney cancer is a common urological malignancy worldwide with an increasing incidence in recent years. Among all subtypes, renal cell carcinoma (RCC) represents the most predominant malignancy in kidney. Clinicians faced a major challenge to select the most effective and suitable treatment regime for patients from a wide range of modalities, despite improved understanding and diagnosis of RCC.
Objective
Recently, organoid culture gained more interest as the 3D model is shown to be highly patient specific which is hypothetically beneficial to the investigation of precision medicine. Nonetheless, the development and application of organotypic culture in RCC is still immature, therefore, the primary objective of this study was to establish an organoid model for RCC. Materials and Methods Patients diagnosed with renal tumor and underwent surgical intervention were recruited. RCC specimen was collected and derived into organoids. Derived organoids were validated by histological examminations, sequencing and xenograft. Drug response of organoids were compared with resistance cell line and patients' clinical outcomes.
Results
Our results demonstrated that organoids could be successfully derived from renal tumor and they exhibited high concordance in terms of immunoexpressional patterns. Sequencing results also depicted concordant mutations of driver genes in both organoids and parental tumor tissues. Critical and novel growth factors were discovered during the establishment of organoid model. Besides, organoids derived from renal tumor exhibited tumorigenic properties in vivo. In addition, organoids recapitulated patient's in vivo drug resistance and served as a platform to predict responsiveness of other therapeutic agents.
Conclusion
Our RCC organoid model recaptiluated histological and genetic features observed in primary tumors. It also served as a potential platform in drug screening for RCC patients, though future studies are necessary before translating the outcomes into clinical practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong.
ORCID-Profile: Ryan Tsz-Hei Tse
Förderung
- Chinese University of Hong Kong
Zitieren
APA
Tse, R. T., Wong, C. Y., Ding, X., Cheng, C. K., Chow, C., Chan, R. C., Ng, J. H., Tang, V. W., Chiu, P. K., Teoh, J. Y., Wong, N., To, K. F., & Ng, C. F. (2024). The establishment of kidney cancer organoid line in drug testing. Cancer Medicine, 13(12). https://doi.org/10.1002/cam4.7432
Vancouver
Tse RT, Wong CY, Ding X, Cheng CK, Chow C, Chan RC, et al. The establishment of kidney cancer organoid line in drug testing. Cancer Medicine. 2024;13(12). doi:10.1002/cam4.7432
BibTeX
@article{Tse2024,
author = {Tse, Ryan Tsz-Hei and Wong, Christine Yim-Ping and Ding, Xiaofan and Cheng, Carol Ka-Lo and Chow, Chit and Chan, Ronald Cheong-Kin and Ng, Joshua Hoi-Yan and Tang, Victor Wai-Lun and Chiu, Peter Ka-Fung and Teoh, Jeremy Yuen-Chun and Wong, Nathalie and To, Ka-Fai and Ng, Chi-Fai},
title = {The establishment of kidney cancer organoid line in drug testing},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {12},
doi = {10.1002/cam4.7432}
}
EUVIMED